Determination of haloperidol in serum by Markit-M Haloperidol and its clinical application

E. Oguchi, S. Kanba, K. Watanabe, G. Yagi

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Today, with an increasing medicolegal environment, therapeutic drug monitoring (TDM) has become more essential. The concentration of HPD in the serum is an effective way to safely monitor the clinical use of HPD. Markit-M Haloperidol, an enzyme-immunoassay, was developed as an assay method of HPD in the serum to have a simpler and quicker procedure with a higher sensitivity than the other previous HPD assay, the property of which was studied in the reproducibility test, the recovery test, the dilution test and the specificity test as well as in the correlation to compare with Markit Haloperidol which is the former enzyme immunoassay. Five mg of HPD (i.v.) was injected into schizophrenic patients and followed by a time course of HPD serum concentration; a high correlation (corrective coefficient: r = 0.965) was found bwtween the 2 assays. Other basic examinations showed good results, including high specificity. Its higher sensitivity, speed and simplicity make this new assay advantageous as well as easily applicable and available for HPD drug therapy monitoring.

Original languageEnglish
Pages (from-to)233-239
Number of pages7
JournalJapanese Journal of Neuropsychopharmacology
Volume16
Issue number4
Publication statusPublished - May 11 1994

Fingerprint

Haloperidol
Drug Monitoring
Immunoenzyme Techniques
Serum
Drug Therapy

All Science Journal Classification (ASJC) codes

  • Clinical Psychology
  • Pharmacology
  • Psychiatry and Mental health
  • Pharmacology (medical)

Cite this

Determination of haloperidol in serum by Markit-M Haloperidol and its clinical application. / Oguchi, E.; Kanba, S.; Watanabe, K.; Yagi, G.

In: Japanese Journal of Neuropsychopharmacology, Vol. 16, No. 4, 11.05.1994, p. 233-239.

Research output: Contribution to journalArticle

Oguchi, E. ; Kanba, S. ; Watanabe, K. ; Yagi, G. / Determination of haloperidol in serum by Markit-M Haloperidol and its clinical application. In: Japanese Journal of Neuropsychopharmacology. 1994 ; Vol. 16, No. 4. pp. 233-239.
@article{54c7a5bcc49d429fab17602d53eddb50,
title = "Determination of haloperidol in serum by Markit-M Haloperidol and its clinical application",
abstract = "Today, with an increasing medicolegal environment, therapeutic drug monitoring (TDM) has become more essential. The concentration of HPD in the serum is an effective way to safely monitor the clinical use of HPD. Markit-M Haloperidol, an enzyme-immunoassay, was developed as an assay method of HPD in the serum to have a simpler and quicker procedure with a higher sensitivity than the other previous HPD assay, the property of which was studied in the reproducibility test, the recovery test, the dilution test and the specificity test as well as in the correlation to compare with Markit Haloperidol which is the former enzyme immunoassay. Five mg of HPD (i.v.) was injected into schizophrenic patients and followed by a time course of HPD serum concentration; a high correlation (corrective coefficient: r = 0.965) was found bwtween the 2 assays. Other basic examinations showed good results, including high specificity. Its higher sensitivity, speed and simplicity make this new assay advantageous as well as easily applicable and available for HPD drug therapy monitoring.",
author = "E. Oguchi and S. Kanba and K. Watanabe and G. Yagi",
year = "1994",
month = "5",
day = "11",
language = "English",
volume = "16",
pages = "233--239",
journal = "Japanese Journal of Neuropsychopharmacology",
issn = "1340-2544",
number = "4",

}

TY - JOUR

T1 - Determination of haloperidol in serum by Markit-M Haloperidol and its clinical application

AU - Oguchi, E.

AU - Kanba, S.

AU - Watanabe, K.

AU - Yagi, G.

PY - 1994/5/11

Y1 - 1994/5/11

N2 - Today, with an increasing medicolegal environment, therapeutic drug monitoring (TDM) has become more essential. The concentration of HPD in the serum is an effective way to safely monitor the clinical use of HPD. Markit-M Haloperidol, an enzyme-immunoassay, was developed as an assay method of HPD in the serum to have a simpler and quicker procedure with a higher sensitivity than the other previous HPD assay, the property of which was studied in the reproducibility test, the recovery test, the dilution test and the specificity test as well as in the correlation to compare with Markit Haloperidol which is the former enzyme immunoassay. Five mg of HPD (i.v.) was injected into schizophrenic patients and followed by a time course of HPD serum concentration; a high correlation (corrective coefficient: r = 0.965) was found bwtween the 2 assays. Other basic examinations showed good results, including high specificity. Its higher sensitivity, speed and simplicity make this new assay advantageous as well as easily applicable and available for HPD drug therapy monitoring.

AB - Today, with an increasing medicolegal environment, therapeutic drug monitoring (TDM) has become more essential. The concentration of HPD in the serum is an effective way to safely monitor the clinical use of HPD. Markit-M Haloperidol, an enzyme-immunoassay, was developed as an assay method of HPD in the serum to have a simpler and quicker procedure with a higher sensitivity than the other previous HPD assay, the property of which was studied in the reproducibility test, the recovery test, the dilution test and the specificity test as well as in the correlation to compare with Markit Haloperidol which is the former enzyme immunoassay. Five mg of HPD (i.v.) was injected into schizophrenic patients and followed by a time course of HPD serum concentration; a high correlation (corrective coefficient: r = 0.965) was found bwtween the 2 assays. Other basic examinations showed good results, including high specificity. Its higher sensitivity, speed and simplicity make this new assay advantageous as well as easily applicable and available for HPD drug therapy monitoring.

UR - http://www.scopus.com/inward/record.url?scp=0028288546&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028288546&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0028288546

VL - 16

SP - 233

EP - 239

JO - Japanese Journal of Neuropsychopharmacology

JF - Japanese Journal of Neuropsychopharmacology

SN - 1340-2544

IS - 4

ER -